Recombinant Adenovirus-p53 Gene Therapy for Advanced Unresectable Soft-Tissue Sarcomas

Area of Science:

• Oncology
• Gene Therapy
• Radiation Oncology

Background:

• Soft-tissue sarcomas (STS) are challenging to treat, especially in advanced, unresectable stages.
• Current treatments like radiotherapy and chemotherapy offer limited efficacy and poor prognoses for advanced STS.

Purpose of the Study:

• To retrospectively evaluate the efficacy and safety of recombinant adenovirus-p53 (rAd-p53) gene therapy combined with radiotherapy and hyperthermia.
• To assess the impact of this combined therapy on disease control, survival outcomes, and adverse events in advanced unresectable STS patients.

Main Methods:

• A retrospective study included 71 patients with advanced unresectable STS.
• Patients were divided into two groups: 36 received rAd-p53 plus radiotherapy and hyperthermia (p53 group), and 35 received radiotherapy and hyperthermia alone (control group).
• Efficacy, survival, and adverse events were compared between the groups.

Main Results:

• The p53 group demonstrated a significantly higher disease control rate (83.33% vs. 54.29%) and a lower progressive disease rate (16.67% vs. 45.71%) compared to the control group.
• rAd-p53 treatment significantly improved progression-free survival and overall survival.
• Cox regression analysis indicated that rAd-p53 treatment significantly reduced the risks of disease progression or death.

Conclusions:

• rAd-p53 gene therapy combined with radiotherapy and hyperthermia is an effective strategy for improving therapeutic outcomes in advanced unresectable STS.
• This combination therapy offers a new and promising treatment option for patients with advanced STS.
• The primary adverse event associated with rAd-p53 therapy was transient fever, with no significant differences in other adverse events between groups.